WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2005103084) POLY-N-ACETYL GLUCOSAMINE (PNAG/DPNAG)-BINDING PEPTIDES AND METHODS OF USE THEREOF
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2005/103084    International Application No.:    PCT/US2005/013694
Publication Date: 03.11.2005 International Filing Date: 21.04.2005
IPC:
C07K 16/00 (2006.01), A61K 39/085 (2006.01), C07K 16/12 (2006.01)
Applicants: THE BRIGHAM AND WOMEN'S HOSPITAL, INC. [US/US]; 75 Francis Street, Boston, MA 02115 (US) (For All Designated States Except US).
BETH ISRAEL DEACONESS MEDICAL CENTER, INC. [US/US]; 330 Brookline Avenue, Boston, MA 02215 (US) (For All Designated States Except US).
PIER, Gerald, B. [US/US]; (US) (For US Only).
KELLY-QUINTOS, Casie, Anne [US/US]; (US) (For US Only).
CAVACINI, Lisa [US/US]; (US) (For US Only).
POSNER, Marshall, R. [US/US]; (US) (For US Only)
Inventors: PIER, Gerald, B.; (US).
KELLY-QUINTOS, Casie, Anne; (US).
CAVACINI, Lisa; (US).
POSNER, Marshall, R.; (US)
Agent: TREVISAN, Maria, A.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US)
Priority Data:
60/564,105 21.04.2004 US
Title (EN) POLY-N-ACETYL GLUCOSAMINE (PNAG/DPNAG)-BINDING PEPTIDES AND METHODS OF USE THEREOF
(FR) PEPTIDES DE LIAISON A POLY-N-ACETYL GLUCOSAMINE (PNAG/DPNAG) ET LEURS PROCEDES D'UTILISATION
Abstract: front page image
(EN)The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.
(FR)L'invention concerne des peptides, en particulier des anticorps monoclonaux humains, qui se lient spécifiquement au poly-N-acétyl glucosamine (PNAG), par exemple le PNAG staphylococcique, sous forme acétylée, partiellement acétylée et/ou totalement déacétylée. L'invention concerne en outre des procédés d'utilisation de ces peptides dans le diagnostic, la prophylaxie et la thérapie d'infections par des bactéries qui expriment PNAG, notamment des staphylocoques et E. coli. Certains anticorps selon l'invention renforcent l'élimination opsonophagocytaire et la protection in vivo contre des bactéries qui expriment le PNAG telles que, notamment, les staphylocoques et E. coli. L'invention concerne enfin des compositions de ces peptides, y compris des compositions pharmaceutiques, ainsi que des variants d'équivalence fonctionnelle de ces peptides.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)